DOCSLIB.ORG

Clinical Chemistry (ISSN 0009-9147) Is Published Monthly by the American Association for Clinical Chemistry, 1850 K Street, Suite 625, Washington, DC 20006

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Chemistry (ISSN 0009-9147) Is Published Monthly by the American Association for Clinical Chemistry, 1850 K Street, Suite 625, Washington, DC 20006 Contents VolumeClinical 53, NumberChemistry 12 EDITORIAL Untargeted Metabolomic Analysis Hits the Target. M.J. Bennett 2037 OPINION Glucose: A Simple Molecule That Is Not Simple to Quantify. R. Gambino 2040 ARTICLES MOLECULAR DIAGNOSTICS AND GENETICS Tentacle ProbesTM: Differentiation of Difficult Single-Nucleotide Polymorphisms and Deletions by Presence or Absence of a Signal in Real-Time PCR. B.C. Satterfield, D.A. Kulesh, D.A. Norwood, L.P. Wasieloski, Jr., M.R. Caplan, and J.A.A. West 2042 Development of a Focused Oligonucleotide-Array Comparative Genomic Hybridization Chip for Clinical Diagnosis of Genomic Imbalance. Y. Shen, M. Irons, D.T. Miller, S.W. Cheung, V. Lip, X. Sheng, K. Tomaszewicz, H. Shao, H. Fang, H.S. Tang, C.A. Walsh, O. Platt, J.F. Gusella, and B.-L. Wu 2051 Global Sequencing Approach for Characterizing the Molecular Background of Hereditary Iron Disorders. S. Cunat, M. Giansily-Blaizot, M. Bismuth, F. Blanc, O. Dereure, D. Larrey, A. Le Quellec, P. Pouderoux, C. Rose, I. Raingeard, E. Renard, J.-F. Schved, P. Aguilar-Martinez, and the CHU Montpellier AOI 2004 Working Group 2060 Detailed Technical Analysis of Urine RNA-Based Tumor Diagnostics Reveals ETS2/Urokinase Plasminogen Activator to Be a Novel Marker for Bladder Cancer. M. Hanke, I. Kausch, G. Dahmen, D. Jocham, and J.M. Warnecke 2070 IL18 Haplotypes Are Associated with Serum IL-18 Concentrations in a Population-Based Study and a Cohort of Individuals with Premature Coronary Heart Disease. S.R. Thompson, P.A. McCaskie, J.P. Beilby, J. Hung, M. Jennens, C. Chapman, P. Thompson, and S.E. Humphries 2078 EVIDENCE-BASED LABORATORY MEDICINE AND TEST UTILIZATION National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. NACB Writing Group Members: A.H.B. Wu, A.S. Jaffe, F.S. Apple, R.L. Jesse, G.L. Francis, D.A. Morrow, L. Kristin Newby, J. Ravkilde, W.H. Wilson Tang, and R.H. Christenson, NACB Committee Members: R.H. Christenson, F.S. Apple, C.P. Cannon, G.L. Francis, R.L. Jesse, D.A. Morrow, L. Kristin Newby, J. Ravkilde, A.B. Storrow, W.H. Wilson Tang, and A.H.B. Wu 2086 Renal Dysfunction Is a Confounder for Plasma Natriuretic Peptides in Detecting Heart Dysfunction in Uremic and Idiopathic Dilated Cardiomyopathies. M. Codognotto, A. Piccoli, M. Zaninotto, M. Mion, M. Plebani, U. Vertolli, F. Tona, L. Ruzza, A. Barchita, and G.M. Boffa 2097 Clinical Chemistry (ISSN 0009-9147) is published monthly by the American Association for Clinical Chemistry, 1850 K Street, Suite 625, Washington, DC 20006. New subscriptions, renewals, changes of address, back issues, and all customer service questions should be addressed to: AACC, Subscription Department, 1850 K Street, Suite 625, Washington, DC 20006. Telephone (202) 857-0717 or 1 (800) 892-1400; fax (202) 887-5093; e-mail [email protected]. Subscription rates: Institutional subscription USA $927, elsewhere $1069. Individual subscription USA $279, elsewhere $434. Airmail outside USA is an additional $260. Individual subscriptions are for personal use and not to be used in a library. Periodicals postage paid at Washington, DC and at additional mailing offices. Postmaster: Send address changes to Clinical Chemistry, 1850 K Street, Suite 625, Washington, DC 20006. Copyright © 2007 The American Association for Clinical Chemistry. 2A Clinical Chemistry December 2007 PROTEOMICS AND PROTEIN MARKERS Modified Form of the Fibrinogen B␤ Chain (des-Gln B␤), a Potential Long-Lived Marker of Pancreatitis. D. Schmidt and S.O. Brennan 2105 Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide. P.A. Kavsak, D.T. Ko, A.M. Newman, G.E. Palomaki, V. Lustig, A.R. MacRae, and A.S. Jaffe 2112 CANCER DIAGNOSTICS MS-FLAG, a Novel Real-Time Signal Generation Method for Methylation-Specific PCR. C. Bonanno, E. Shehi, D. Adlerstein, and G.M. Makrigiorgos 2119 LIPIDS,LIPOPROTEINS, AND CARDIOVASCULAR RISK FACTORS Development of a Homogeneous Assay to Measure Remnant Lipoprotein Cholesterol. K. Miyauchi, N. Kayahara, M. Ishigami, H. Kuwata, H. Mori, H. Sugiuchi, T. Irie, A. Tanaka, S. Yamashita, and T. Yamamura 2128 DRUG MONITORING AND TOXICOLOGY Buprenorphine and Norbuprenorphine in Hair of Pregnant Women and Their Infants after Controlled Buprenorphine Administration. R.S. Goodwin, D.G. Wilkins, O. Averin, R.E. Choo, J.R. Schroeder, D.R. Jasinski, R.E. Johnson, H.E. Jones, and M.A. Huestis 2136 ENDOCRINOLOGY AND METABOLISM Analytical Validation and Biological Evaluation of a High–Molecular-Weight Adiponectin ELISA. M.K. Sinha, T. Songer, Q. Xiao, J.H. Sloan, J. Wang, S. Ji, W.E. Alborn, R.A. Davis, M.M. Swarbrick, K.L. Stanhope, B.M. Wolfe, P.J. Havel, T. Schraw, R.J. Konrad, P.E. Scherer, and J.S. Mistry 2144 Association of C-Reactive Protein with Surrogate Measures of Insulin Resistance among Nondiabetic US Adults: Findings from National Health and Nutrition Examination Survey 1999–2002. Y.-X. Meng, E.S. Ford, C. Li, A. Quarshie, A.M. Al-Mahmoud, W. Giles, G.H. Gibbons, and G. Strayhorn 2152 Determination of Bioavailable Testosterone [Non–Sex Hormone–Binding Globulin (SHBG)-Bound Testosterone] in a Population of Healthy French Men: Influence of Androstenediol on Testosterone Binding to SHBG. F. Giton, S. Urien, C. Born, J. Tichet, J. Gue´chot, J. Callebert, F. Bronsard, J.P. Raynaud, and J. Fiet 2160 AUTOMATION AND ANALYTICAL TECHNIQUES Metabolomics Identifies Perturbations in Human Disorders of Propionate Metabolism. W.R. Wikoff, J.A. Gangoiti, B.A. Barshop, and G. Siuzdak 2169 Visual Recognition and Efficient Isolation of Apoptotic Cells with Fluorescent-Magnetic-Biotargeting Multifunctional Nanospheres. E.-Q. Song, G.-P. Wang, H.-Y. Xie, Z.-L. Zhang, J. Hu, J. Peng, D.-C. Wu, Y.-B. Shi, and D.-W. Pang 2177 CLINICAL IMMUNOLOGY Antibodies against Synthetic Deamidated Gliadin Peptides as Predictors of Celiac Disease: Prospective Assessment in an Adult Population with a High Pretest Probability of Disease. S. Niveloni, E. Sugai, A. Cabanne, H. Vazquez, J. Argonz, E. Smecuol, M.L. Moreno, F. Nachman, R. Mazure, Z. Kogan, J.C. Gomez, E. Maurin˜o, and J.C. Bai 2186 (Continued) 3A Contents Volume 53, Number 12 INFECTIOUS DISEASE Midregional Pro-A-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia. M. Masia´, J. Papassotiriou, N.G. Morgenthaler, I. Herna´ndez, C. Shum, and F. Gutie´rrez 2193 TECHNICAL BRIEFS Effects of 7 Hemoglobin Variants on the Measurement of Glycohemoglobin by 14 Analytical Methods. S.-T. Lee, C.W. Weykamp, Y.-W. Lee, J.-W. Kim, and C.-S. Ki 2202 Mass Spectrometry–Based Detection of Hemoglobin E Mutation by Allele-Specific Base Extension Reaction. J.C.H. Tsang, P. Charoenkwan, K.C.K. Chow, Y. Jin, C. Wanapirak, T. Sanguansermsri, Y.M.D. Lo, and R.W.K. Chiu 2205 Development and Validation of an Automated Thawing and Mixing Workcell. C.D. Hawker, W.L. Roberts, A. DaSilva, G.D. Stam, W.E. Owen, D. Curtis, B.-S. Choi, and T.A. Ring 2209 Detection of Factor VIII Gene Mutations by High-Resolution Melting Analysis. A.D. Laurie, M.P. Smith, and P.M. George 2211 LETTERS TO THE EDITOR The Origin of Circulating Free DNA. M. van der Vaart and P.J. Pretorius 2215 A Receptor-Mediated Mechanism to Support Clinical Observation of Altered Albumin Variants. J.T. Andersen and I. Sandlie 2216 Stability of Plasma Homocysteine, S-Adenosylmethionine, and S-Adenosylhomocysteine in EDTA, Acidic Citrate, and Primavette™ Collection Tubes. U. Hu¨ bner, H. Schorr, R. Eckert, J. Geisel, and W. Herrmann 2217 From Syndrome to Spectrum: What Evolution Suggests about the Status of the Metabolic Syndrome. A. Matheson 2218 Effect of Corticosteroid Therapy on Low-Molecular–Weight Protein Markers of Kidney Function. A. Bo¨kenkamp, C.A.R.C. Laarman, K.I. Braam, J.A.E. van Wijk, W.A. Kors, M. Kool, J. de Valk, A.A. Bouman, M.D. Spreeuwenberg, and B. Stoffel-Wagner 2219 Ammonium 5-Bromo-7-fluorobenzo-2-oxa-1,3-diazole-4-sulphonate: A New Fluorogenic Reagent for the Determination of Aminothiols by HPLC. G. Cevasco, A.M. Mumot, C. Scapolla, and S. Thea 2221 44 Single-Nucleotide Polymorphisms Expressed by Placental RNA: Assessment for Use in Noninvasive Prenatal Diagnosis of Trisomy 21. A.T.J.I. Go, A. Visser, M.A.M. Mulders, M.A. Blankenstein, J.M.G. van Vugt, and C.B.M. Oudejans 2223 BOOK,SOFTWARE, AND WEB SITE REVIEWS Tietz’s Applied Laboratory Medicine, 2nd ed. Mitchell G. Scott, Ann M. Gronowski, and Charles S. Eby, eds. K. Jung 2225 CORRECTION Can Whole-Blood Samples Be Stored over 24 Hours without Compromising Stability of C-Reactive Protein, Retinol, Ferritin, Folic Acid, and Fatty Acids in Epidemiologic Research. M. van Eijsden, M.F. van der Wal, G. Hornstra, and G.J. Bonsel 2226 4A (Continued) Clinical Chemistry December 2007 THE CLINICAL CHEMIST D.E. Bruns 2227 INVITED REVIEWERS—2007 2229 ACCENTா—CONTINUING EDUCATION CREDIT FOR READERS OF CLINICAL CHEMISTRY For more information go to www.aacc.org/ccj/accent 5A Editorial Untargeted Metabolomic Analysis Hits the Target Propionic (PA) and methylmalonic (MMA) acidemias ways have been used mainly in targeted studies of are inborn errors of the metabolism of several important candidate alternate pathways such as studies of the in- amino acids, the side chain of the cholesterol molecule, volvement of the Krebs cycle in PA and MMA. Targeted and dietary odd chain-length fatty acids. PA results analysis is likely to provide incomplete knowledge of all from a deficiency of mitochondrial propionyl-CoA car- metabolic interactions that may result from a single gene boxylase, an enzyme that requires biotin as a cofactor defect.
Load more

Recommended publications
  • Breast Cysts
    Beaumont Hospital Patient Information on Breast Cysts PRINTROOM PDF 23012017 SUP190B What are breast cysts? The breasts are made up of lobules (milk- producing glands) and ducts (tubes that carry milk to the nipple), surrounded by fatty and supportive tissue. Sometimes fluid-filled sacs develop in the breast tissue. These are breast cysts. It’s thought that they develop naturally as the breast ages and changes. Although you can develop breast cysts at any age, they are most common in women over 35 who haven’t yet reached menopause. They occur more frequently as women approach the menopause and usually resolve or are less frequent after it. However, they may persist or develop in women who take hormone replacement therapy (HRT) after menopause. Cysts can feel soft if they are near the surface of the skin, or like a hard lump if they’re deeper in the breast tissue. They can develop anywhere in the breast, but are more commonly found in the upper half. For some women cysts can feel uncomfortable or even painful. Before a period cysts may become larger, and feel sore and tender. It’s common to develop one or more cysts either in one breast or both breasts –and this is nothing to worry about. It is also common to have many cysts without knowing about them. How are they found? Cysts usually become noticeable as a lump in the breast, or are sometimes found by chance when you have a breast examination or routine mammography. When you have a breast examination your GP will sometimes be able to say whether the lump feels like a cyst.
    [Show full text]
  • Approach to Breast Mass
    APPROACH TO BREAST MASS Resident Author: Kathleen Doukas, MD, CCFP Faculty Advisor: Thea Weisdorf, MD, CCFP Creation Date: January 2010, Last updated: August 2013 Overview In primary care, breast lumps are a common complaint among women. In one study, 16% of women age 40-69y presented to their physician with a breast lesion over a 10-year period.1 Approximately 90% of these lesions will be benign, with fibroadenomas and cysts being the most common.2 Breast cancer must be ruled out, as one in ten woman who present with a new lump will have cancer.1 Diagnostic Considerations6 Benign: • Fibroadenoma: most common breast mass; a smooth, round, rubbery mobile mass, which is often found in young women; identifiable on US and mammogram • Breast cyst: mobile, often tender masses, which can fluctuate with the menstrual cycle; most common in premenopausal women; presence in a postmenopausal woman should raise suspicion for malignancy; ultrasound is the best method for differentiating between a cystic vs solid structure; a complex cyst is one with septations or solid components, and requires biopsy • Less common causes: Fat necrosis, intraductal papilloma, phyllodes tumor, breast abscess Premalignant: • Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia: Premalignant breast lesions with 4-6 times relative risk of developing subsequent breast cancer;8 often found incidentally on biopsy and require full excision • Carcinoma in Situ: o Ductal Carcinoma in Situ (DCIS): ~85% of in-situ breast cancers; defined as cancer confined to the duct that
    [Show full text]
  • Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience
    Article Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience Eiji Higashihara,*† Vicente E. Torres,*‡ Arlene B. Chapman,§ Jared J. Grantham, Kyongtae Bae,¶ Terry J. Watnick,** †† † ‡‡ ‡‡ ‡‡ 2 Shigeo Horie, Kikuo Nutahara, John Ouyang, Holly B. Krasa, Frank S. Czerwiec, for the TEMPO4 and 156-05-002 Study Investigators Summary †Kyorin University Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of School of Medicine, end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression Mitaka, Tokyo, Japan; ‡ in animal models. Mayo Clinic College of Medicine, Rochester, Minnesota; §Emory Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kid- University School of ney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of Medicine, Atlanta, ʈ tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, Georgia; Kansas and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR University Medical Center, Kansas City, (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses Kansas; ¶University of of primary and secondary end points included LMM using all subject data and mixed model repeated mea- Pittsburgh School of sures (MMRM) of change from baseline at each year. Pearson correlation tested the association between Medicine, Pittsburgh, log-TKV and eGFR changes. Pennsylvania; **Johns Hopkins University, Baltimore, Maryland; Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events ††Teikyo University (AEs), with AEs accounting for six of 12 withdrawals.
    [Show full text]
  • Index to the NLM Classification 2011
    National Library of Medicine Classification 2011 Index Disease see Tyrosinemias 1-8 5,12-diHETE see Leukotriene B4 1,2-Benzopyrones see Coumarins 5,12-HETE see Leukotriene B4 1,2-Dibromoethane see Ethylene Dibromide 5-HT see Serotonin 1,8-Dihydroxy-9-anthrone see Anthralin 5-HT Antagonists see Serotonin Antagonists 1-Oxacephalosporin see Moxalactam 5-Hydroxytryptamine see Serotonin 1-Propanol 5-Hydroxytryptamine Antagonists see Serotonin Organic chemistry QD 305.A4 Antagonists Pharmacology QV 82 6-Mercaptopurine QV 269 1-Sar-8-Ala Angiotensin II see Saralasin 7S RNA see RNA, Small Nuclear 1-Sarcosine-8-Alanine Angiotensin II see Saralasin 8-Hydroxyquinoline see Oxyquinoline 13-cis-Retinoic Acid see Isotretinoin 8-Methoxypsoralen see Methoxsalen 15th Century History see History, 15th Century 8-Quinolinol see Oxyquinoline 16th Century History see History, 16th Century 17 beta-Estradiol see Estradiol 17-Ketosteroids WK 755 A 17-Oxosteroids see 17-Ketosteroids A Fibers see Nerve Fibers, Myelinated 17th Century History see History, 17th Century Aardvarks see Xenarthra 18th Century History see History, 18th Century Abate see Temefos 19th Century History see History, 19th Century Abattoirs WA 707 2',3'-Cyclic-Nucleotide Phosphodiesterases QU 136 Abbreviations 2,4-D see 2,4-Dichlorophenoxyacetic Acid Chemistry QD 7 2,4-Dichlorophenoxyacetic Acid General P 365-365.5 Organic chemistry QD 341.A2 Library symbols (U.S.) Z 881 2',5'-Oligoadenylate Polymerase see Medical W 13 2',5'-Oligoadenylate Synthetase By specialties (Form number 13 in any NLM
    [Show full text]
  • Research Article Application Value of Mathematical Models of Diffusion-Weighted Magnetic Resonance Imaging in Differentiating Breast Cancer Lesions
    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2021, Article ID 1481271, 8 pages https://doi.org/10.1155/2021/1481271 Research Article Application Value of Mathematical Models of Diffusion-Weighted Magnetic Resonance Imaging in Differentiating Breast Cancer Lesions Xiaolong Jiang, Chao Chen, Jie Liu, and Sheng Liu e Affiliated Nanhua Hospital, Department of Radiology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China Correspondence should be addressed to Sheng Liu; [email protected] Received 7 July 2021; Accepted 17 August 2021; Published 30 August 2021 Academic Editor: Songwen Tan Copyright © 2021 Xiaolong Jiang et al. ,is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To determine the application value of the mono-exponential model, dual-exponential model, and stretched-exponential model of MRI with diffusion-weighted imaging (DWI) in breast cancer (BC) lesions. Methods. Totally 64 cases with BC admitted to our hospital between June 2019 and October 2020 were enrolled in this study. ,ey had 71 lesions in total, including 40 benign tumor lesions (including 9 breast cyst lesions) and 31 malignant tumor lesions. After DWI examination, with normal glands as control, mono-exponential model (ADC) map, dual-exponential model (Standard-ADC) map, slow apparent diffusion coefficient (Slow- ADC) map, fast-apparent diffusion coefficient (Fast-ADC) map, and stretched-exponential model (DDC) map were processed, and corresponding values were generated. ,en, the situation and significance of each parameter in breast cysts, benign breast tumor lesions, and malignant tumor lesions were analyzed.
    [Show full text]
  • Benign Breast Cyst Without Associated Gynecomastia in a Male Patient: a Case Report Parsian Et Al
    Breast Imaging: Benign Breast Cyst without Associated Gynecomastia in a Male Patient: A Case Report Parsian et al. Benign Breast Cyst without Associated Gynecomastia in a Male Patient: A Case Report Sana Parsian1*, Habib Rahbar1, Mara H. Rendi2, Constance D. Lehman1 1. Department of Radiology, University of Washington, Seattle, USA 2. Department of Pathology, University of Washington, Seattle, USA * Correspondence: Sana Parsian, MD., Department of Radiology, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue E. Seattle, WA 98109, USA ( [email protected]) Radiology Case. 2011 Nov; 5(11):35-40 :: DOI: 10.3941/jrcr.v5i11.869 ABSTRACT Benign simple breast cysts are commonly seen in female breasts and can present as palpable masses. They are distinctly uncommon, however, in the male breast. We report a case of simple benign cyst of the breast in a 58- year-old man newly diagnosed with mantel cell lymphoma. The cyst was first identified incidentally on a staging contrast-enhanced chest computed www.RadiologyCases.com tomography. Further evaluation with mammography and ultrasound revealed a mass that would be typically characterized as a benign simple cyst, but was biopsied since cysts are not known to occur in male breasts. Pathology results from ultrasound-guided core needle biopsy revealed benign cyst and focal fibrosis which was concordant with the imaging findings. In this case report, we will briefly discuss breast cysts in men and their imaging features including mammography and ultrasound. CASE REPORT JournalRadiology of Case Reports Bilateral diagnostic digital mammogram revealed a 10 CASE REPORT millimeter oval shaped equal density mass with partially A 58-year-old Caucasian man, with recent diagnosis of circumscribed, partially obscured margins in the subareolar mantle cell lymphoma underwent chest, abdomen, and pelvis left breast, corresponding to the CT finding, without evidence computed tomography (CT) for staging purposes.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
    [Show full text]
  • 65 Y/O Female, Lower Abdominal Pain A19
    2016年05月20日 中華民國放射線醫學會 住院醫師閱片測驗 出題醫院 亞東紀念醫院影像醫學科 Q1 What is most likely in a 35-year-old patient? CT with bone window T1 weighted with Gd A1 What bone lesion is most likely in this 35-year-old female? ANS： Fibrous dysplasia Q2 76y/o male, patient with severe headache What is the diagnosis & its cause in this case? FLAIR or dark-fluid T2 Pre-contrast T1 weighted A2 ANS： Acute venous infarct & left transverse sinus thrombosis Q3 What primitive carotid-vertebrobasilar connection is? The red arrow is the left carotid artery A3 ANS： Persistent trigeminal artery Q4 11 y/o boy, with seizure Coronal T2 weighted Sagittal T1 weighted with Gd. A4 ANS： Ependymoma Q5 42 y/o male, patient with head injury FLAIR or dark water T2 T1 weighted with Gd. A5 ANS： Enlarged perivascular space or dilated Virchow-Robin space Q6 44 y/o male, Right homonymous hemianopia for 7 days DWI ADC T1 FLAIR T2 CE T1 A6 ANS： Subacute infarction at left occipital lobe Q7 69 y/o male, 到院前心跳停止, Acute conscious change, sent to ER A7 ANS： Hypoxic ischemic encephalopathy Q8 50 y/o female, Orthostatic headache A8 ANS： Spontaneous Intracranial Hypotension Spontaneous Intracranial Hypotension • Syndrome in which low CSF volume results in orthostatic headache • Generally due to CSF leakage through a dural defect • May be related to predisposing underlying structural weakness of the spinal meninges • Key Imaging Features: related to Monro-Kellie hypothesis: loss of CSF from subarachnoid space → increase in total intracranial blood volume causing enlargement of dural venous sinuses, epidural vertebral venous plexus, and pituitary gland.
    [Show full text]
  • Breast Cyst Aspiration (Ultrasound Guided)
    St. Luke’s Breast & Bone Health 319/369-7216 Breast Cyst Aspiration (Ultrasound Guided) What is a breast cyst? A breast cyst is a fluid-filled sac (like a tiny balloon). Typically breast cysts occur in women between the ages of 35 and 50, but are most commonly found in those approaching menopause. If you are past menopause and taking hormone therapy, breast cysts may still develop. Breast cyst size may vary and change depending on where you are in your menstrual cycle. Most breast cysts occur in the upper half of your breast. They often enlarge and become tender or painful just before your period. They may seem to appear overnight. Breast cysts move easily to the touch. They may feel either soft or hard. When they are close to the skin’s surface, they may feel like a blister, smooth on the outside, but fluid-filled on the inside. However, if the cyst is found more deeply in the breast, it may feel hard as there is more tissue surrounding it. Women may have cysts in their breasts and not even be aware of them. Cysts are known to come back; in fact some women may get cysts several times during their life. Cysts are not cancer and do not change into cancer. However, there are rare instances where a cancer is growing within them or close to them. Simple cysts do not typically require treatment. For some women, breast cysts can be quite painful and they decide to have them drained. What is a cyst aspiration and why is it done? The process of aspirating (draining) breast cysts is a simple one.
    [Show full text]
  • What Is a Breast Cyst (Pdf 59KB)
    Patient education • CLINICAL PRACTICE What is a breast cyst? The New South Wales Breast Cancer Institute. A breast cyst is a collection of fluid in a mammogram, they can sometimes be or cysts that show worrying features on the breast. Fluid is being produced and seen as a smooth, round mass in the breast imaging or pathology tests. reabsorbed constantly in the milk ducts tissue. On ultrasound, they are usually a in the breast. When a duct becomes smooth, round, well defined, and black. Can they come back? blocked, or the amount of fluid produced Sometimes cysts do not have these typical Cysts can come back after aspiration, or is greater than the amount absorbed, fluid features and are difficult to distinguish from new cysts can develop in the nearby breast accumulates causing cysts. Cysts can be solid (nonfluid) lesions just by looking, and tissue. Cysts that do come back after single or multiple. They can come and go, require further investigation. These are aspiration usually take several months to and vary during the menstrual cycle. When sometimes referred to as ‘complex cysts’. recur. Any that come back within a few cysts become large, they can cause a lump. weeks may require further testing. Classically the lump is smooth, soft, and How are they treated? moves easily. If the fluid is under tension, Cysts causing no symptoms and showing Are they cancerous? it can feel firm when examined. Cysts are typical benign (noncancerous) features on Breast cysts are not cancerous, and often tender. Even if there is no distinct imaging require no treatment.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids. It is notable that breast cysts, as for Antiperspiran breast cancers, start most frequently in the upper outer quadrant of the breast, which is the region closest to the site of underarm antiperspirant application. Mechanistic Copyright: © 2019 Philippa D Darbre. evidence is reviewed for a link between aluminium levels in breast tissue, cyst Clinical Dermatology: Research And Therapy. This is an open access article formation and development of breast cancer. If excessive use of antiperspirant is a distributed under the Creative cause of breast cysts, then reduction or cessation of use could provide a preventative Commons Attribution License, which or even treatment strategy. Furthermore, if cyst formation from antiperspirant use is permits unrestricted use, distribution, an indicator of increased risk for breast cancer, then reduction in use of antiperspirant and reproduction in any medium, provided the original work is properly could also provide a strategy for reducing breast cancer risk.
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]